NewBiologix and Synastra Join Forces to Advance rAAV Manufacturing for Duchenne Gene Therapy

The collaboration brings together Synastra’s expertise in genomic engineering, AAV vector design, rare-disease gene therapy, and translational development with NewBiologix’s proprietary cell engineering and rAAV manufacturing technologies.

The post NewBiologix and Synastra Join Forces to Advance rAAV Manufacturing for Duchenne Gene Therapy appeared first on GEN - Genetic Engineering and Biotechnology News.